Heart Failure

In an analysis, low GI/GL dietary patterns resulted in a reduction in HbA1c, compared with control diets with a mean difference of −0.31.

Data show the change in 24-hour ambulatory systolic blood pressure was significant between treatment and control groups with a reduction of 7.1 mm Hg.

Kelly Chin, MD discusses the recent FDA approval of selexipag IV and breakthroughs in the cardiovascular care space.

Data show the expression levels of miR-214, BNP, NT-proBNP, and sST2 were significantly higher compared to the control group.

Data show a patient aged 65 years would have an extrapolated mean event-free survival of 6.2 years for placebo and 8.3 years for dapagliflozin, at a gain of 2.1 years.

In this series of HCPLive® State of the Science, 4 experts discuss knowledge and treatment in the cardiovascular risk management space.

Data show dapagliflozin was projected to add 0.63 quality-adjusted life-years at an incremental lifetime cost of $42, 800.

Data show no significant difference in time to first heart failure rehospitalization or death compared to usual care in patients with HFrEF.

New guidelines on aortic valve implantation in risk groups with aortic stenosis shifted from risk strata to a focus on patient age and life expectancy.

Data show a significant association between wearable tracker use and increased physical activity during a 15-week period.

The EMPEROR-Preserved trial demonstrated safety and efficacy of empagliflozin for patients with heart failure across spectrum of ejection fraction.

Dapagliflozin and the SGLT2 inhibitor class may have untapped potential far beyond the reduction of heart failure hospitalization risk.

Resolution of iron deficiency was associated with lower mortality; however, mortality risk was similar following resolution of anemia.

Patients with a preserved ejection fraction saw a significant reduction in risk for cardiovascular-related adverse events and mortality.

A new analysis of the SCORED and SOLOIST trials suggests sotagliflozin could provide substantial benefit for reducing risk of cardiovascular death and worsening heart failure among patients with HFrEF and HFpEF.

The SGLT-2 inhibitor drug class is expanding into treatment indications experts could not have predicted. Learn how DAPA-HF contributed to the understanding of dapagliflozin.

Older patients who maintained the multi-domain rehabilitation program saw improvements in various markers of physical function.

Though the combination heart failure therapy did provide overall benefit versus ramipril in post-heart attack patients, the rate of events reduced was not considered significant.

James Januzzi, MD, and Javed Butler, MD, MPH, MBA, discuss emerging agents, vericiguat and intravenous (IV) iron, in the treatment landscape for heart failure with reduced ejection fraction and advice for community physicians managing patients with heart failure.

Cardiology experts discuss challenges in achieving the optimal therapy for patients with heart failure and the influence of patient lifestyle and medical factors.

Insights on approaching the initiation of SGLT2 inhibitors for the treatment of heart failure with reduced ejection fraction.

Javed Butler, MD, MPH, MBA, reviews the historical background of using SGLT2 inhibitors and the impact on patients with heart failure with reduced ejection fraction.

Evaluating the facilitation of an MRA (mineralocorticoid receptor antagonist) when using an optimal adjuvant medical therapy for the treatment of heart failure.

Anti-VEGF administration did increase the risk of nonocular hemorrhages, mostly in patients with AMD.

Investigators collect study data from lengthy questionnaires relating to diet and demographics, finding that a high glycemic index correlates to more adverse effects in patients.